HUAKANG(SH:605077) Zheng Quan Zhi Xing·2025-08-21 16:47Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders, with total share capital as of August 20, 2025, being considered for adjustments based on changes in share capital due to convertible bonds, share buybacks, or other factors [1]. Company Overview - The company is listed on the Shanghai Stock Exchange under the stock code 605077, with the stock name "Huakang Shares" [2][3]. - As of the end of the reporting period, the total assets of the company amounted to approximately 7.56 billion yuan, reflecting an increase of 8.19% compared to the previous year [3]. - The net profit attributable to shareholders of the listed company for the reporting period was approximately 150.41 million yuan, a 2.89% increase from the previous year [3]. Financial Performance - The company's operating revenue for the reporting period reached approximately 1.87 billion yuan, representing a year-on-year growth of 37.32% [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately 121.51 million yuan, showing a decrease of 6.56% compared to the same period last year [3]. - The net cash flow from operating activities was not specified in the provided data [3]. Shareholder Information - The total number of shareholders as of the reporting period was 17,091 [3]. - The top shareholder, Chen Deshui, holds 15.58% of the shares, while other significant shareholders include Cheng Xinping and Xu Xiaorong, each holding approximately 5.51% and 5.18% respectively [5]. Important Developments - The company anticipates revenue growth in 2025 due to the production launch of the first phase of the Zhoushan Huakang project, which involves a 1 million-ton corn deep processing health food ingredient project [5].